Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE